Gaps in Sexually Transmitted Infection Screening Among Men Who Have Sex With Men in Pre-exposure Prophylaxis (PrEP) Care in the United States

Christina Chandra,¹ Kevin M. Weiss,¹ Colleen F. Kelley,² Julia L. Marcus,³ and Samuel M. Jenness¹

¹Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, ²Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA, and ³Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA

Background. The US Centers for Disease Control and Prevention (CDC) recommends comprehensive sexually transmitted infection (STI) screening every 3–6 months for men who have sex with men (MSM) using human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The gaps between these recommendations and clinical practice by region have not been quantified.

Methods. We used survey data collected from the internet-based ARTnet study between 2017 and 2019 on STI screening among MSM across the United States, stratified by current, prior, and never PrEP use. Poisson regression models with robust error variance were used to model factors, including residence in the Southeast, associated with consistent (“always” or “sometimes”) exposure site-specific STI screening during PrEP care.

Results. Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had used PrEP in the past, and 75% had never used PrEP. Among ever PrEP users, 87%, 78%, 57%, and 64% reported consistent screening for STIs by blood sample, urine sample or urethral swab, rectal swab, or pharyngeal swab, respectively, during PrEP care. Compared to PrEP users in all other regions, PrEP users in the Southeast were significantly less likely to be consistently screened for urogenital (adjusted prevalence ratio [aPR], 0.86; 95% confidence interval [CI], .76–.98) and rectal STIs (aPR, 0.76; 95% CI, .62–.93) during PrEP care.

Conclusions. Substantial gaps exist between CDC recommendations for STI screening during PrEP care and current clinical practice, particularly for rectal and pharyngeal exposure sites that can harbor asymptomatic infections and for MSM in Southeast states where the STI burden is substantial.

Keywords. HIV; pre-exposure prophylaxis; sexually transmitted infections; screening; men who have sex with men.

In the United States, cases of the major reportable bacterial sexually transmitted infections (STIs)—syphilis, gonorrhea, and chlamydia—increased by up to 71% between 2014 and 2018, reaching all-time highs [1]. Rates of new human immunodeficiency virus (HIV) diagnoses have remained stable overall but increased in key subgroups during this time [2]. Men who have sex with men (MSM) are disproportionately affected by STIs and HIV, accounting for more than half of new infectious syphilis cases, 40% of gonorrhea cases, and 66% of HIV cases in 2018 despite only representing 4% of the population [1–3]. Additionally, more than half of new HIV diagnoses in 2018 occurred in the South, which also has the highest STI rates [1, 2].

One hypothesis for the increase in STI cases among MSM has been the growing use of HIV pre-exposure prophylaxis (PrEP). In a meta-analysis, the pooled STI prevalence among

PrEP users within 3 months of PrEP initiation was 24%, and STI incidence was estimated at 72 per 100 person-years among persistent PrEP users globally [4]. US studies have found that STI prevalence or incidence increased among MSM after PrEP initiation [5, 6]. The difference in STI rates before and after PrEP initiation could result from multiple factors, including increased detection of cases from more frequent screening in PrEP care, changes in sexual risk behavior after PrEP initiation (“risk compensation”), and trends in sexual behavior and STI rates that predate PrEP [1, 7–10]. Many PrEP users are at elevated risk of STIs because PrEP is recommended for MSM with a history of inconsistent condom use and multiple partners [11].

The US Centers for Disease Control and Prevention (CDC) recommends comprehensive STI screening every 3–6 months for MSM using PrEP [11]. This includes blood tests to screen for syphilis, and urine samples and urethral, pharyngeal, and rectal swabs for gonorrhea and chlamydia infections. Prior modeling research suggested that although STI diagnoses may initially increase with expanded PrEP use due to variations of risk compensation, routine STI screening and treatment during PrEP care could prevent over 40% of gonorrhea and chlamydia cases among MSM over 10 years [12]. These results were partially attributed to increased treatment

Received 11 March 2020; editorial decision 24 June 2020; accepted 17 July 2020; published online July 23, 2020.

Correspondence: S. M. Jenness, Emory University, 1520 Clifton Rd, Atlanta, GA 30323 (samuel.m.jenness@emory.edu).

Clinical Infectious Diseases® 2021;73(7):e2261–9

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/ciaa1033

of asymptomatic STIs that would have otherwise been undiagnosed. These projections assumed complete adherence to PrEP-related STI screening and treatment recommendations; secondary model scenarios projected that STI incidence could increase if fewer than 50% of PrEP users were consistently screened and treated for STIs.

Quantifying any gaps between PrEP STI screening recommendations and clinical practice is therefore critical to understanding the role of PrEP care in STI control. Several studies have evaluated this in different regions, finding lower rates of STI screening than recommended [7, 13–16]. Although these studies provide important evidence regarding gaps in PrEP care, there are still no national-level studies of MSM that have compared these gaps across geographic regions. Geographic heterogeneity in clinical practice is important to understand because of the regional differences in infrastructure for PrEP services (eg, the ability to assess kidney function and serological confirmation of hepatitis B status for PrEP eligibility) and the spatial clustering of STIs in the Southeast [17, 18]. Differences in STI screening practices may also reflect state-level factors that impact PrEP care, including access to healthcare (eg, Medicaid expansion) and social determinants of health that may vary by state (eg, housing stability, employment) [19, 20]. By examining these differences, we may better understand the role that geographically focused efforts—such as the federal Ending the HIV Epidemic initiative—may play in stemming both the HIV and STI epidemics in the Southeast [21].

In this study, we compared STI screening among MSM by PrEP use history in a study of MSM in the United States. We then evaluated factors associated with consistent STI screening at PrEP care visits, including residence in the Southeast and recent sexual exposure at anatomical sites. We hypothesized that there would be strong geographic differences in STI screening consistency among PrEP users even after controlling for demographic and behavioral factors.

METHODS

Study Design

ARTnet was a cross-sectional web-based study of MSM in the United States conducted between 2017 and 2019 [22]. The study recruited participants through the national American Men's Internet Survey (AMIS), with a response rate of 53% (4904/9295) [23]. ARTnet eligibility criteria included male sex at birth, current male identity, lifetime history of sexual activity with another man, and age between 15 and 65 years. The study, provided only in English, surveyed participants about recent sexual behaviors, HIV and STI screening, and egocentric network data [24]. We restricted the participants in this analysis to PrEP-eligible MSM, defined as MSM who had ever had an HIV test and who self-reported as HIV-negative. The Emory

University Institutional Review Board reviewed and approved the study.

Measures

We quantified participant-reported data on HIV and STI screening from blood samples, urine sample/urethral swabs, and rectal and pharyngeal swabs at PrEP care visits and any HIV or STI screening in the past 12 months. Participants who had ever used PrEP were asked: "At these PrEP (ie, Truvada) check-up visits, how often did you get tested for HIV and sexually transmitted diseases (STDs)? STDs could include gonorrhea, chlamydia, and syphilis." Participants could answer "Always," "Sometimes," "Rarely," or "Never" for HIV screening or STI screening site/method: throat (pharyngeal swab), anus (rectal swab), genital/penis (urine sample/urethral swab), or blood sample. We assumed blood-based STI screening was used to possibly screen for syphilis, because blood samples are necessary for syphilis screening whereas swabs and urine samples are used for nucleic acid amplification tests (NAATs), the gold standard for gonorrhea and chlamydia testing. For statistical models, we dichotomized the outcomes to consistent screening ("Always" or "Sometimes") versus inconsistent screening ("Rarely" or "Never").

We then investigated correlates of consistent STI screening. We considered age group, race/ethnicity, current health insurance, annual household income, recent sexual exposure at anatomical site, and geographic region of residence. Using data on the 5 most recent reported partners in the past year, respondents were classified as having been exposed at the urethra (any insertive anal or insertive oral intercourse), rectum (any receptive anal intercourse), or pharynx (any receptive oral intercourse). For geography, we considered census division and state by matching reported residential ZIP codes against census data [22]. Our primary exposure of interest was residence in 12 Southeast states as defined by the US Bureau of Economic Analysis: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [25].

Statistical Analysis

Our primary research objective was to quantify the association between residence in Southeast states and consistent screening for STIs among MSM who were currently using or had previously used PrEP. We first estimated the bivariable prevalence ratios between our hypothesized correlates—age, race/ethnicity, current health insurance, annual household income, recent sexual exposure at anatomical site, and geography—and consistent site-specific STI screening using Poisson regression with robust error variance and complete case analysis. In multivariable Poisson regression models, we estimated the prevalence ratios between our primary exposure (residence in a Southeast state) and consistent STI screening adjusted for 4 variables that we

hypothesized would confound this relationship: age, race/ethnicity, annual household income, and sexual exposure at anatomical site. We did not control for variables that we considered mediators of the associations, such as health insurance that may vary by state as a result of Medicaid expansion. All analyses were conducted in R 3.6.1 [26]. Analysis scripts are provided in a GitHub repository (<https://github.com/EpiModel/PrEP-STI-Test>), and the primary data are available upon request.

RESULTS

After excluding PrEP-ineligible participants, 3259 MSM were included in this analysis. Of those, 631 (19%) were currently using PrEP at the time of survey completion, 178 (6%) had previously used PrEP, and 2450 (75%) had never used PrEP. Table 1 presents the demographics and HIV/STI screening history by PrEP use. Overall, 74% were non-Hispanic white, 51% were aged 15–34 years, and 23% resided in Southeast states.

Table 1. Characteristics of Pre-exposure Prophylaxis (PrEP)-Eligible ARTnet Participants, Stratified by PrEP Use History

	Total ^a		Current PrEP Use		Prior PrEP Use		Never Used PrEP	
	N or Mean	% ^b or SD	N or Mean	% or SD	N or Mean	% or SD	N or Mean	% or SD
Total sample	3259	100.0	631	100.0	178	100.0	2450	100.0
Race/ethnicity								
Black (non-Hispanic)	134	4.1	28	4.4	4	2.3	102	4.2
Hispanic	422	12.9	81	12.8	23	12.9	318	13.0
Other (non-Hispanic)	283	8.7	53	8.4	11	6.2	219	8.9
White (non-Hispanic)	2420	74.3	469	74.3	140	78.7	1811	73.9
Age	37.3	13.6	39.5	12.4	34.1	11.5	36.9	13.9
15–24	713	21.9	71	11.3	36	20.2	606	24.7
25–34	947	29.1	196	31.1	76	42.7	675	27.6
35–44	518	15.9	122	19.3	26	14.6	370	16.3
45–54	573	17.6	149	23.6	24	13.5	400	16.3
55–65	508	15.6	93	14.7	16	9.0	399	16.3
Residence in census division^c								
Pacific	562	17.2	155	24.6	31	17.4	376	15.3
Mountain	281	8.6	30	4.8	21	11.8	230	9.4
West North Central	187	5.7	32	5.1	13	7.3	142	5.8
East North Central	466	14.3	92	14.6	25	14.0	349	14.2
West South Central	323	9.9	61	9.7	11	6.2	251	10.2
East South Central	132	4.1	19	3.0	6	3.4	107	4.4
South Atlantic	701	21.5	119	18.9	35	19.7	547	22.3
Middle Atlantic	442	13.6	92	14.6	20	11.2	330	13.5
New England	165	5.1	31	4.9	16	9.0	118	4.8
Residence in Southeast^d								
Yes	760	23.3	121	19.2	33	18.5	606	24.7
No	2499	76.7	510	80.8	145	81.5	1844	75.3
Health insurance								
Private	2441	76.4	516	82.2	128	71.9	1797	75.2
Public	514	16.1	94	15.0	33	18.5	387	16.2
None	242	7.6	18	2.9	17	9.6	207	8.7
Annual household income								
\$0 to \$19 999	372	12.3	54	9.3	18	10.7	300	13.2
\$20 000 to \$39 999	574	19.1	93	16.1	34	20.2	447	19.7
\$40 000 to \$74 999	861	28.6	153	26.4	56	33.3	652	28.8
\$75 000 or more	1206	40.0	279	48.2	60	35.7	867	38.3
Screened for HIV in past 12 months								
Yes	2106	71.9	561	98.2	129	79.6	1416	64.5
No	822	28.1	10	1.8	33	20.4	779	35.5
Screened for an STI in past 12 months								
Yes	1677	54.4	547	89.1	122	70.9	1008	43.8
No	1408	45.6	67	10.9	50	28.1	1291	56.2

Abbreviations: HIV, human immunodeficiency virus; PrEP, pre-exposure prophylaxis; SD, standard deviation; STI, sexually transmitted infection; USD, US dollars.

^a Totals may not add up to sample total due to missing data for health insurance, annual household income, and screening for HIV and STIs in the past 12 months.

^b Column percents.

^c https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf.

^d Residence in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

Residents in the Southeast were generally underrepresented, accounting for 25% of MSM who had never used PrEP and 19% of both current and prior PrEP users. Four-fifths (82%) of current PrEP users reported having any private health insurance compared with 72% of prior PrEP users and 75% of never PrEP users. Only 3% of current PrEP users were uninsured compared with 10% of prior PrEP users and 9% of never PrEP users. A higher proportion of current PrEP users reported screening for a bacterial STI (without specifying specimen collected) in the past year (89%), compared to prior PrEP users (71%) and never PrEP users (44%). Similarly, 98% of current PrEP users were screened for HIV in the past year compared to 80% of prior PrEP users and 65% of never PrEP users.

Among MSM who had ever used PrEP, 84% of current users reported attending PrEP care visits at least every 3 months compared to 71% of prior PrEP users (Table 2). Overall, 91% of MSM who had ever used PrEP were always screened for HIV at their PrEP care visits. Greater proportions of current PrEP users, compared to prior PrEP users, reported “always” being screened for STIs by throat swab (44% vs 35%), rectal swab (37% vs 32%), blood (possibly for syphilis; 70% vs 57%), and urine sample/urethral swab (59% vs 50%) at PrEP care visits. In contrast, MSM who had ever used PrEP had also reported “never” providing a rectal swab (35%), throat swab (28%), and urine sample/urethral swab (17%) for STI screening during PrEP care visits.

Table 2. Frequency of Pre-exposure Prophylaxis (PrEP) Care Visits and HIV/STI Screening at PrEP Care Visits Among Men Who Have Sex with Men With Current or Prior PrEP Use

	Total ^a		Current PrEP Use		Prior PrEP Use	
	N	%	N	%	N	%
Total sample	809	100.0	631	100.0	178	100.0
Frequency of PrEP care visits						
Every month	23	2.9	13	2.1	10	5.7
Every 3 months	629	78.3	514	82.0	115	65.3
Every 6 months	83	10.3	75	12.0	8	4.5
Every 9 months	3	0.4	1	0.2	2	1.1
Every 12 months	8	1.0	8	1.3	0	0.0
Returned only once	21	2.6	3	0.5	18	10.2
Returned at some other interval of time	11	1.4	6	1.0	5	2.8
Did not return regularly	25	3.1	7	1.1	18	10.2
Frequency of HIV screening at PrEP care visits		0				
Always	685	91.1	566	92.5	119	85.0
Sometimes	50	6.6	40	6.5	10	7.1
Rarely	7	0.9	3	0.5	4	2.9
Never	10	1.3	3	0.5	7	5.0
Frequency of throat swab for STI screening at PrEP care visits						
Always	316	42.5	267	44.1	49	35.3
Sometimes	161	21.6	134	22.1	27	19.4
Rarely	56	7.5	44	7.3	12	8.6
Never	211	28.4	160	26.4	51	36.7
Frequency of rectal swab for STI screening at PrEP care visits						
Always	270	36.2	226	37.2	44	31.7
Sometimes	155	20.8	128	21.1	27	19.4
Rarely	58	7.8	50	8.2	8	5.8
Never	263	35.3	203	33.4	60	43.2
Frequency of blood sample for STI screening at PrEP care visits						
Always	492	67.4	415	69.9	77	56.6
Sometimes	143	19.6	114	19.2	29	21.3
Rarely	32	4.4	21	3.5	11	8.1
Never	63	8.6	44	7.4	19	14.0
Frequency of urine sample/urethral swab for STI screening at PrEP care visits						
Always	425	57.3	356	59.0	69	49.6
Sometimes	150	20.2	128	21.2	22	15.8
Rarely	42	5.7	33	5.5	9	6.5
Never	125	16.8	86	14.3	39	28.1

Abbreviations: HIV, human immunodeficiency virus; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

^a Totals may not add up to sample total due to missing data.

A higher percentage of MSM who had ever used PrEP reported consistent possible screening for syphilis (87%) and urogenital STI screening (78%) (Table 3) compared to pharyngeal (64%) and rectal STI screening (57%) (Table 4). Compared to MSM aged 15–24 years, older MSM aged 55–65 years had the lowest levels of consistent screening for urogenital STIs (80% vs 71%), pharyngeal STIs (70% vs 60%), and rectal STIs (67% vs

53%) (Tables 3 and 4). Consistent screening was reported less in Southeast states for urogenital STI screening (66% vs 80% in all other states), pharyngeal STI screening (55% vs 66%), and rectal STI screening (44% vs 60%). Respondents reporting recent exposure at corresponding anatomical sites also reported more consistent screening for urogenital (78% vs 68% among those unexposed) and rectal STIs (60% vs 44%). Proportions of

Table 3. Bivariable Associations of Consistent Possible Syphilis and Urogenital Sexually Transmitted Infection Screening With Demographic and Behavioral Factors Among Men Who Have Sex With Men Who Have Ever Used Pre-exposure Prophylaxis

	Possible Syphilis Screening ^a (N = 730)						Urogenital STI Screening (N = 742)					
	Consistent ^b		Inconsistent		PR	95% CI	Consistent		Inconsistent		PR	95% CI
	N	%	N	%			N	%	N	%		
Total sample	635	87.0	95	13.0			575	77.5	167	22.5		
Age												
15–24	75	83.3	15	16.7	1.00	...	73	80.2	18	19.8	1.00	...
25–34	215	87.8	30	12.2	1.05	.95, 1.17	201	80.1	50	19.9	1.00	.89, 1.12
35–44	123	90.4	13	9.6	1.09	.97, 1.21	104	75.4	34	24.6	.94	.82, 1.08
45–54	140	85.9	23	14.1	1.03	.92, 1.15	127	77.9	36	22.1	.97	.85, 1.11
55–65	82	85.4	14	14.6	1.02	.91, 1.16	70	70.7	29	29.3	.88	.75, 1.04
Race/ethnicity												
Black (Non-Hispanic)	30	93.8	2	6.3	1.00	...	28	87.5	4	12.5	1.00	...
Hispanic	84	91.3	8	8.7	.97	.87, 1.09	78	84.8	14	15.2	.97	.83, 1.13
Other (Non-Hispanic)	53	91.4	5	8.6	.97	.87, 1.10	45	77.6	13	22.4	.89	.73, 1.07
White (Non-Hispanic)	468	85.4	80	14.6	.91	.83, 1.00	424	75.7	136	24.3	.87	.75, 0.99
Health Insurance												
None	28	84.8	5	15.2	1.00	...	23	69.7	10	30.3	1.00	...
Public	98	87.5	14	12.5	1.03	.88, 1.21	91	79.8	23	20.2	1.15	.90, 1.46
Private	507	87.1	75	12.9	1.03	.89, 1.19	459	77.5	133	22.5	1.11	.88, 1.40
Annual Household Income												
\$0 to \$19 999	54	83.1	11	16.9	1.00	...	50	76.9	15	23.1	1.00	...
\$20 000 to \$39 999	86	80.4	21	19.6	.97	.84, 1.12	87	79.1	23	20.9	1.03	.87, 1.21
\$40 000 to \$74 999	165	87.3	24	12.7	1.05	.93, 1.19	147	75.4	48	24.6	.98	.84, 1.14
\$75 000 or more	279	89.1	34	10.9	1.07	.96, 1.21	244	77.2	72	22.8	1.00	.87, 1.16
Residence in Census Division												
New England	36	92.3	3	7.7	1.00	...	33	80.5	8	19.5	1.00	...
Middle Atlantic	89	85.6	15	14.4	.93	.82, 1.05	86	79.6	22	20.4	.99	.83, 1.18
East North Central	89	84.0	17	16.0	.91	.80, 1.03	83	77.6	24	22.4	.96	.80, 1.16
West North Central	29	74.4	10	25.6	.81	.66, .99	24	60.0	16	40.0	.75	.56, 1.00
South Atlantic	119	86.9	18	13.1	.94	.84, 1.05	93	67.9	44	32.1	.84	.70, 1.02
East South Central	18	85.7	3	14.3	.93	.76, 1.13	13	61.9	8	38.1	.77	.53, 1.11
West South Central	62	89.9	7	10.1	.97	.86, 1.10	57	82.6	12	17.4	1.03	.85, 1.24
Mountain	34	79.1	9	20.9	.86	.72, 1.02	32	74.4	11	25.6	.92	.73, 1.17
Pacific	159	92.4	13	7.6	1.00	.91, 1.11	154	87.5	22	12.5	1.09	.93, 1.28
Residence in Southeast^c												
No	517	87.2	76	12.8	1.00	...	484	80.0	121	20.0	1.00	...
Yes	118	86.1	19	13.9	0.99	.92, 1.06	91	66.4	46	33.6	.83	.73, 0.94
Exposure at Anatomical Site^d												
No							15	68.2	7	31.8	1.00	...
Yes							560	77.8	160	22.2	1.14	.86, 1.52

Abbreviations: CI, confidence interval; PR, prevalence ratio; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

^a Participants who provided blood samples for STI screening were considered to be possibly screened for syphilis, because blood samples are needed for syphilis screening, whereas swabs and urine samples can be used for gold standard testing of gonorrhea and chlamydia.

^b Consistent screening defined as always or sometimes (versus rarely or never) being screened at PrEP care visits compared.

^c Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

^d Defined as any insertive anal intercourse or receiving oral sex for urogenital STI screening.

Table 4. Bivariable Associations of Consistent Rectal and Pharyngeal STI Screening With Demographic and Behavioral Factors Among Men Who Have Sex With Men Who Have Ever Used Pre-exposure Prophylaxis

	Rectal STI Screening (N = 746)						Pharyngeal STI Screening (N = 744)					
	Consistent		Inconsistent		PR	95% CI	Consistent		Inconsistent		PR	95% CI
	N	%	N	%			N	%	N	%		
Total sample	425	57.0	321	43.0			477	64.1	267	35.9		
Age												
15–24	61	67.0	30	33.0	1.00	...	63	70.0	27	30.0	1.00	...
25–34	146	57.9	106	42.1	.86	.72, 1.03	163	64.9	88	35.1	.93	.79, 1.09
35–44	74	53.6	64	46.4	.80	.65, .99	89	64.5	49	35.5	.92	.77, 1.11
45–54	91	55.2	74	44.8	.82	.67, 1.00	102	61.8	63	38.2	.88	.74, 1.06
55–65	53	53.0	47	47.0	.79	.63, 1.00	60	60.0	40	40.0	.86	.70, 1.06
Race/ethnicity												
Black (Non-Hispanic)	16	50.0	16	50.0	1.00	...	19	59.4	13	40.6	1.00	...
Hispanic	57	62.0	35	38.0	1.24	.85, 1.82	61	66.3	31	33.7	1.12	.81, 1.54
Other (Non-Hispanic)	39	67.2	19	32.8	1.34	.91, 1.99	43	74.1	15	25.9	1.25	.90, 1.73
White (Non-Hispanic)	313	55.5	251	44.5	1.11	.78, 1.58	354	63.0	208	37.0	1.06	.79, 1.42
Health insurance^a												
None	19	57.6	14	42.4	1.00	...	22	66.7	11	33.3	1.00	...
Public	58	50.0	58	50.0	.87	.62, 1.23	74	63.8	42	36.2	.96	.73, 1.26
Private	347	58.4	247	41.6	1.01	.75, 1.37	380	64.2	212	35.8	.96	.75, 1.23
Annual household income												
\$0 to \$19 999	35	53.0	31	47.0	1.00	...	44	66.7	22	33.3	1.00	...
\$20 000 to \$39 999	59	53.6	51	46.4	1.01	.76, 1.35	62	56.4	48	43.6	.85	.67, 1.07
\$40 000 to \$74 999	109	55.9	86	44.1	1.05	.81, 1.37	125	64.4	69	35.6	.97	.79, 1.18
\$75 000 or more	187	58.8	131	41.2	1.11	.87, 1.42	206	65.0	111	35.0	.97	.81, 1.18
Residence in census Division												
New England	29	70.7	12	29.3	1.00	...	30	73.2	11	26.8	1.00	...
Middle Atlantic	65	60.2	43	39.8	.85	.66, 1.09	74	69.2	33	30.8	.95	.76, 1.18
East North Central	57	52.8	51	47.2	.75	.57, 0.97	59	54.6	49	45.4	.75	.58, .96
West North Central	21	52.5	19	47.5	.74	.52, 1.06	24	61.5	15	38.5	.84	.62, 1.15
South Atlantic	65	46.1	76	53.9	.65	.50, .85	79	56.0	62	44.0	.77	.60, .97
East South Central	7	33.3	14	66.7	.47	.25, .89	9	42.9	12	57.1	.59	.35, .99
West South Central	40	58.0	29	42.0	.82	.62, 1.09	47	68.1	22	31.9	.93	.73, 1.19
Mountain	19	45.2	23	54.8	.64	.43, .94	20	47.6	22	52.4	.65	.45, .94
Pacific	122	69.3	54	30.7	.98	.79, 1.22	135	76.7	41	23.3	1.05	.86, 1.28
Residence in Southeast^b												
No	364	60.1	242	39.9	1.00	...	400	66.2	204	33.8	1.00	...
Yes	61	43.6	79	56.4	.73	.59, .89	77	55.0	63	45.0	.83	.71, .97
Exposure at Anatomical Site^c												
No	61	44.2	77	55.8	1.00	...	15	62.5	9	37.5	1.00	...
Yes	364	59.9	244	40.1	1.35	1.11, 1.65	462	64.2	258	35.8	1.03	.75, 1.41

Abbreviations: CI, confidence interval; PR, prevalence ratio; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

^a Consistent screening defined as always or sometimes (vs rarely or never) being screened at PrEP care visits compared.

^b Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

^c Defined as any receptive anal intercourse for rectal STI screening and any performance of oral sex on a partner for pharyngeal STI screening within the past year.

MSM reporting consistent screening of pharyngeal STIs were about the same between MSM reporting sexual exposure and none at the pharynx (64% vs 63%).

Among MSM who had ever used PrEP, age, race/ethnicity, health insurance, annual household income, census division, and residence in Southeast states were not significantly associated with possible syphilis screening at PrEP care visits (Table 3). For urogenital, rectal, and pharyngeal STIs, there was a general trend of MSM aged 15–24 years reporting consistent

screening compared to MSM aged 55–65 years at PrEP care visits (Tables 3 and 4). In unadjusted analyses, MSM in Southeast states reported a lower prevalence of consistent urogenital (prevalence ratio [PR], 0.83; 95% confidence interval [CI], .73–.94), rectal (PR, 0.73; 95% CI, .59–.89), and pharyngeal (PR, 0.83; 95% CI, .71–.97) STI screening during PrEP care (Table 4). MSM who reported exposure at the rectum reported a 35% higher prevalence of consistent rectal STI screening at PrEP care visits (PR, 1.35; 95% CI, 1.11–1.65). Prevalence of

consistent STI screening was not substantially different between MSM reporting exposure at anatomical site compared to those with no exposure for urogenital (PR, 1.14; 95% CI, .86–1.52) and pharyngeal STIs (PR, 1.03; 95% CI, .75–1.41) (Tables 3 and 4).

In adjusted models, a smaller proportion of MSM in Southeast states reported consistent STI screening compared to MSM in other regions (Table 5). MSM in the Southeast had 14% lower prevalence of consistent urogenital STI screening (adjusted prevalence ratio [aPR], 0.86; 95% CI, .76–.98) and 24% lower prevalence of consistent rectal STI screening (aPR, 0.76; 95% CI, .62–.93) during PrEP care. A lower prevalence of MSM in Southeast states compared to all other regions of the country reported consistent pharyngeal STI screening during PrEP care (aPR, 0.87; 95% CI, .74–1.03). The prevalence of consistent possible syphilis screening was not substantially different between MSM in the Southeast and MSM in all other regions (aPR, 1.02; 95% CI, .95–1.10).

DISCUSSION

In this national study of MSM in the United States, consistency of STI screening at PrEP care visits was lower than recommended, especially for rectal and pharyngeal infections that are mostly asymptomatic. Our findings also highlight the regional variation in gaps between recommendations and PrEP clinical

practice overall and raise concerns about whether comprehensive PrEP care as currently practiced would be effective for STI control, particularly in the Southeast where the burden of bacterial STIs is highest [1, 18].

This study contributes to the growing literature on patterns of STI screening within PrEP care. With the exception of one national study [14], research has been limited to individual clinics or health systems, often with limited sample sizes [7, 13, 15, 16]. These studies analyze a variety of data streams, including electronic health records, health insurance claims, or laboratory screening [15, 16, 27]. Many different measures have been used as primary outcomes: screening at last PrEP care visit [13], STI or rectal STI screening in the prior 12 months [7], or proportion screened for STIs within 6 months of PrEP initiation [14]. Our study, in contrast, measured STI screening across PrEP care visits that may better reflect ongoing consistency of clinical practice. We also stratified data by current and prior PrEP use, and more frequent STI screening among current PrEP users compared to prior users was expected given CDC's revised recommendations to more frequent STI screening in 2017.

Despite these different study designs and outcomes, research has consistently shown suboptimal STI screening among PrEP users, especially for extragenital (rectal or pharyngeal) screening [13–16]. Similar to a study conducted in Baltimore, we found that among all site-specific screening, rectal swabs were reported least often [16]. A study in New York City, in contrast, found that pharyngeal STI screening was the least reported (at the last PrEP care visit) [13]. These results are also consistent with findings of infrequent extragenital STI screening among MSM outside of PrEP care [28–30]. Infrequent extragenital screening is a public health concern because of the higher prevalence of asymptomatic chlamydia or gonorrhea infections that may remain undetected [31]. Asymptomatic STIs at these sites also lead to increased risk of HIV infection among partners in the sexual network not using PrEP [24, 32].

Several factors have been found to be associated with more recent or comprehensive STI screening: younger age, white race, college education, reporting exposure at anatomical sites that may trigger screening, and previous syphilis diagnoses [7, 13, 15, 16]. We additionally found that residence in the Southeast was associated with inconsistent urogenital and rectal STI screening, after adjusting for potential confounders. These results have implications for regional improvements of comprehensive PrEP care at the patient, provider, and systems level. MSM have previously noted discomfort in discussing their sexual orientation and subsequently sexual health and behaviors with their primary care providers, emphasizing the importance of patient-provider communication in PrEP care [33]. At the provider level, time constraints, cultural and language barriers, difficulty obtaining a sexual history, and patient privacy concerns have affected HIV providers' ability to conduct routine STI screening [34]. The cost of ancillary

Table 5. Multivariable Associations of Consistent^a Sexually Transmitted Infection Screening With Residence in the Southeast United States^b Among Men Who Have Sex With Men Who Have Ever Used Pre-exposure Prophylaxis

	Adjusted PR ^c	95% CI
Possible syphilis screening^{d,e}		
Residence outside Southeast	1.00	...
Residence in Southeast	1.02	.95, 1.10
Urogenital STI screening		
Residence outside Southeast	1.00	...
Residence in Southeast	.86	.76, .98
Rectal STI screening		
Residence outside Southeast	1.00	...
Residence in Southeast	.76	.62, .93
Pharyngeal STI screening		
Residence outside Southeast	1.00	...
Residence in Southeast	.87	.74, 1.03

Abbreviations: CI, confidence interval; PR, prevalence ratio; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

^a Consistent screening defined as always or sometimes (vs rarely or never) being screened at PrEP care visits compared.

^b Residence in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

^c Adjusted for age, race/ethnicity, annual household income, and sexual exposure at anatomical site.

^d Not adjusted for sexual exposure at anatomical site.

^e Participants who provided blood samples for STI screening were considered to be possibly screened for syphilis, because blood samples are needed for syphilis screening, whereas swabs and urine samples can be used for gold standard testing of gonorrhea and chlamydia.

services associated with PrEP care such as STI screening may also be a barrier, as providers have noted that high cost of medication and health insurance coverage may hinder the real-world effectiveness of PrEP [35]. Related to cost, alternative options should also be considered for undocumented populations. Moreover, 7 of the 12 Southeast states (in our definition) have not expanded Medicaid under the Affordable Care Act, potentially limiting the ability of MSM to obtain adequate coverage for consistent STI screening [36]. Gaps in comprehensive PrEP care may exacerbate the large racial and socioeconomic disparities in HIV and STI incidence in the region [37]. Wider implementation of alternative STI screening approaches, such as self-collected rectal and pharyngeal swabs or home-screening kits, may also improve STI screening coverage for PrEP-using MSM [38, 39].

Limitations

This study has several limitations. First, this web-based sample does not necessarily represent the larger population of MSM with respect to age, race/ethnicity, health insurance, annual household income, and geographic residential location. Most participants were white, had higher income levels, had private health insurance, and lived in the mid-Atlantic/Northeast or the West Coast. Compared to venue-based sampling, web-based sampling of MSM may yield a sample with more non-Hispanic white and higher-income men [40]. The survey was English-only, which may have contributed to the lack of ethnic representativeness of the responses. Additionally, given our focus on the Southeast and that 4% of respondents are Black, our sample critically underrepresents the MSM population in the Southeast. Second, stratifying participant data by the covariates of interest yielded small sample sizes in some categories (reflected in wide confidence intervals for some estimates). Third, we relied on self-reported data, and there may be misclassification of screening frequency due to not understanding what specific STIs are being screened. We may be overestimating consistency of possible syphilis screening, because participants may misinterpret blood draws for HIV screening or other tests at PrEP care visits as inclusive of STI screening. Fourth, the data were also limited in classifying anatomical site exposure because the ARTnet study collected data on a maximum of 5 partners; this may not align with their PrEP care visits. Fifth, we assumed that PrEP users accessed PrEP in their reported residential ZIP Code, but it is possible that prior or current PrEP users accessed PrEP in a different state. Sixth, respondents may have received STI screening outside of PrEP care (eg, through another health-care provider or community-based organization), the frequency of which is not captured in ARTnet. Finally, the STI screening frequency measure (always, sometimes, rarely, or never) allows for an approximate but not perfect estimate of adherence to CDC recommendations, particularly because “sometimes” can represent a wide range of screening frequencies as interpreted

by respondents. For this reason, we used the term “consistent” rather than “as recommended.”

CONCLUSIONS

Data from this large national study of MSM improved the understanding of geographic differences in comprehensive health services for MSM using PrEP. Although a higher proportion of PrEP users reported recent STI screening compared to non-PrEP users, barriers exist to complete adherence to CDC PrEP guidelines of comprehensive screening for STIs at all exposure sites among MSM. This was especially true in Southeast states where the STI burden is high and where the federal government has prioritized funding HIV prevention programs through the Ending the HIV Epidemic initiative [21]. As PrEP is scaled up in the Southeast through this national initiative, resources at the patient, provider, and systems level to support STI screening and treatment as part of PrEP care should simultaneously be strengthened. Otherwise, sub-optimal STI screening in PrEP care may lead to increases in overall STI incidence among MSM.

Notes

Financial support. This work was supported by the National Institutes of Health (grant number R21 MH112449).

Potential conflicts of interest. C. K. reports grants from Gilead Sciences, NIH, and CDC, outside the submitted work. J. M. reports consulting for Kaiser Permanente Northern California on a research grant from Gilead Sciences, outside the submitted work. All other authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. US Dep Health Hum Serv 2019. Available at: <https://www.cdc.gov/std/stats>. Accessed 4 March 2020.
- Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Preliminary). Centers for Disease Control and Prevention, 2019. Available at: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Accessed 4 March 2020.
- Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012; 6:98–107.
- Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. *JAMA Netw Open* 2019; 2:e1917134.
- Montaño MA, Dombrowski JC, Dasgupta S, et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. *AIDS Behav* 2019; 23:548–55.
- Marcus JL, Hurley LB, Hare CB, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. *J Acquir Immune Defic Syndr* 1999 2016; 73:540–6.
- Menza TW, Lipira L, Bhattarai A, Ramirez FJ, Orellana ER. Self-reported screening for rectal sexually transmitted infections among men who have sex with men. *Sex Transm Dis* 2019; 46:683–8.
- Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. *Clin Infect Dis* 2015; 61:1601–3.
- Paz-Bailey G, Mendoza MC, Finlayson T, et al; NHBS Study Group. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. *AIDS* 2016; 30:1985–90.

10. Harawa NT, Holloway IW, Leibowitz A, et al. Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. *AIDS* **2017**; 31:739–40.
11. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. **2018**. Available at: <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>. Accessed 4 March 2020.
12. Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. *Clin Infect Dis* **2017**; 65:712–8.
13. Parsons JT, John SA, Whitfield THF, Cienfuegos-Szalay J, Grov C. Human immunodeficiency virus/sexually transmitted infection counseling and testing services received by gay and bisexual men using preexposure prophylaxis at their last PrEP care visit. *Sex Transm Dis* **2018**; 45:798–802.
14. Huang YA, Tao G, Samandari T, Hoover KW. Laboratory testing of a cohort of commercially insured users of HIV preexposure prophylaxis in the United States, 2011–2015. *J Infect Dis* **2018**; 217:617–21.
15. Spinelli MA, Scott HM, Vittinghoff E, et al. Provider adherence to pre-exposure prophylaxis monitoring guidelines in a large primary care network. *Open Forum Infect Dis* **2018**; 5:ofy099.
16. Schumacher C, Wu L, Chandran A, et al. STI screening among gay, bisexual and other men who have sex with men prescribed PrEP in Baltimore City, Maryland. *Clin Infect Dis* **2020**; 71:2637–44.
17. Sullivan PS, Mena L, Eloppe L, Siegler AJ. Implementation strategies to increase PrEP uptake in the South. *Curr HIV/AIDS Rep* **2019**; 16:259–69.
18. Marotta P. Assessing spatial relationships between race, inequality, crime, and gonorrhea and chlamydia in the United States. *J Urban Health* **2017**; 94:683–98.
19. Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. *PLoS One* **2017**; 12:e0178737.
20. Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. The Promise of pre-exposure prophylaxis for black men who have sex with men: an ecological approach to attitudes, beliefs, and barriers. *AIDS Patient Care STDS* **2016**; 30:282–90.
21. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. *JAMA* **2019**; 321:844–5.
22. Weiss KM, Goodreau SM, Morris M, et al. Egocentric sexual networks of men who have sex with men in the United States: results from the ARTnet study. *Epidemics* **2020**; 30:100386.
23. Zlotorzynska M, Sullivan P, Sanchez T. The annual American Men's internet survey of behaviors of men who have sex with men in the United States: 2016 key indicators report. *JMIR Public Health Surveill* **2019**; 5:e11313.
24. Jenness SM, Weiss KM, Prasad P, Zlotorzynska M, Sanchez T. Bacterial sexually transmitted infection screening rates by symptomatic status among men who have sex with men in the United States: a hierarchical Bayesian analysis. *Sex Transm Dis* **2019**; 46:25–30.
25. BEA Regions. Available at: <https://apps.bea.gov/regional/docs/regions.cfm>. Accessed 4 March 2020.
26. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. **2019**. Available at: <https://www.R-project.org/>. Accessed 4 March 2020.
27. Hevey MA, Walsh JL, Petroll AE. PrEP continuation, HIV and STI testing rates, and delivery of preventive care in a clinic-based cohort. *AIDS Educ Prev* **2018**; 30:393–405.
28. de Voux A, Bernstein KT, Kirkcaldy RD, Zlotorzynska M, Sanchez T. Self-reported extragenital chlamydia and gonorrhea testing in the past 12 months among men who have sex with men in the United States: American Men's internet survey, 2017. *Sex Transm Dis* **2019**; 46:563–70.
29. Barbee LA, Dhanireddy S, Tat SA, Marrazzo JM. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. *Sex Transm Dis* **2015**; 42:590–4.
30. Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. *Clin Infect Dis* **2014**; 58:1564–70.
31. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. *Clin Infect Dis* **2005**; 41:67–74.
32. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. *J Acquir Immune Defic Syndr* **1999** **2010**; 53:537–43.
33. Maloney KM, Krakower DS, Ziobro D, Rosenberger JG, Novak D, Mayer KH. Culturally competent sexual healthcare as a prerequisite for obtaining preexposure prophylaxis: findings from a qualitative study. *LGBT Health* **2017**; 4:310–4.
34. Carter JW Jr, Hart-Cooper GD, Butler MO, Workowski KA, Hoover KW. Provider barriers prevent recommended sexually transmitted disease screening of HIV-infected men who have sex with men. *Sex Transm Dis* **2014**; 41:137–42.
35. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. *AIDS Behav* **2014**; 18:1712–21.
36. Kaiser Family Foundation. Status of state Medicaid expansion decisions: interactive map. Henry J Kais Fam Found **2020**. Available at: <https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/>. Accessed 4 March 2020.
37. Goodreau SM, Rosenberg ES, Jenness SM, et al. Sources of racial disparities in HIV prevalence in men who have sex with men in Atlanta, GA, USA: a modelling study. *Lancet HIV* **2017**; 4:e311–20.
38. Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of chlamydia trachomatis and *Neisseria gonorrhoeae* by use of nucleic acid amplification tests. *J Clin Microbiol* **2009**; 47:1657–62.
39. Fisher M, Wayal S, Smith H, et al; Brighton Home Sampling Kit Project Steering Group. Home sampling for sexually transmitted infections and HIV in men who have sex with men: a prospective observational study. *PLoS One* **2015**; 10:e0120810.
40. Chen YT, Bowles K, An Q, et al. Surveillance among men who have sex with men in the United States: a comparison of web-based and venue-based samples. *AIDS Behav* **2018**; 22:2104–12.